Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended June 30, 1995
Business Overview: Cardinal Health is a national, full-service wholesaler distributing pharmaceuticals, surgical and hospital supplies, therapeutic plasma, and health and beauty care products. The company operates through a network of distribution centers serving hospitals, retail drug stores, and managed care facilities across the continental United States. The company is structured as a holding company with multiple operating subsidiaries.
Key Financial Metrics
| Metric | Fiscal 1995 | Fiscal 1994 |
|---|---|---|
| Net Sales | $7,806,092,000 | $5,790,411,000 |
| Gross Margin | $464,456,000 (5.95%) | $355,172,000 (6.13%) |
| Operating Earnings | $163,639,000 | $85,987,000 |
| Net Earnings (Common Shares) | $84,973,000 | $33,931,000 |
| Earnings Per Share (Diluted) | $2.01 | $0.86 |
| Total Assets | $1,841,804,000 | $1,395,602,000 |
| Long-Term Obligations | $209,250,000 | $210,086,000 |
| Shareholders' Equity | $548,197,000 | $368,494,000 |
| Working Capital | $601,344,000 | $471,082,000 |
| Cash and Equivalents | $40,619,000 | $54,941,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 35% to $7.8 billion, driven by 25% internal growth and acquisitions of Humiston-Keeling, Inc. and Behrens Inc. in fiscal 1995.
- Profitability: Net earnings available for common shares more than doubled to $85.0 million from $33.9 million. Operating earnings rose significantly to $163.6 million.
- Margins: Gross margin percentage declined to 5.95% from 6.13% due to a more competitive market and a higher mix of volume customers requiring lower pricing. However, Selling, General, and Administrative (SG&A) expenses as a percentage of sales improved to 3.85% from 4.03% due to economies of scale.
- Balance Sheet: Total assets grew by $446 million, primarily due to increases in merchandise inventories ($203.6 million) and trade receivables ($175.4 million) to support sales growth. Shareholders' equity increased by $179.7 million, fueled by net earnings and a public offering of common shares.
- Unusual Items: Fiscal 1994 included a $35.9 million charge for Whitmire Merger costs. Fiscal 1993 included a $13.5 million termination fee and $13.7 million in restructuring charges. Fiscal 1995 results do not include significant unusual items.
Guidance, Outlook, and Risks
- Acquisition Activity: The company signed a definitive merger agreement on August 26, 1995, to acquire Medicine Shoppe International, Inc., a franchisor of independent retail pharmacies. The transaction is expected to be accounted for as a pooling-of-interests and involves issuing approximately 6.0 to 6.8 million common shares.
- Liquidity: The company maintains $325 million in line-of-credit agreements, with $322 million available as of June 30, 1995. Management believes capital resources are adequate for anticipated growth and debt service.
- Legal Proceedings: The company is a defendant in consolidated class action antitrust lawsuits ("Brand Name Prescription Drug Litigation") alleging price inflation via chargeback systems. A Judgment Sharing Agreement limits the company's exposure to the lesser of 1% of any judgment or $1 million. Management believes the allegations are without merit.
- Industry Risks: The industry faces cost containment pressure from payers, healthcare reform, and consolidation among customers and manufacturers. The company relies on efficient distribution and value-added services to maintain margins in a highly competitive environment.
Investor Verification Checklist
- Merger Integration: Verify the completion and financial impact of the Medicine Shoppe merger and the integration of Humiston-Keeling and Behrens.
- Margin Trends: Monitor gross margin percentages to ensure the decline stabilizes as the customer mix shifts and specialty business units grow.
- Working Capital Management: Assess the efficiency of inventory and receivables turnover given the significant increases in these assets relative to sales growth.
- Legal Exposure: Track the status of the Brand Name Prescription Drug Litigation to confirm the limited liability cap remains enforceable.
- Debt Structure: Review the maturity schedule of long-term obligations, specifically the $100 million 8% Notes due 1997 and $100 million 6.5% Notes due 2004.